BioPharma and Health Reform: The Good, the Bad, and the Just Plain Ugly

While the prospects for major health reform are unclear, there is more clarity to what biopharma has at stake: A lot. In this issue, The RPM Report presents a guide to the upsides and downsides for the biopharma industry of some of the major issues in health reform and some handicapping of the likelihood of each.